Please assess the completion status of the following clinical trial:

Trial Title: Canadian Pradaxa Acute Stroke Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients will be ≥ 18 years of age.~2. Minor ischemic stroke, defined as NIHSS score ≤ 3. Transient Ischemic Attack (TIA), defined as acute focal neurological deficits, with complete resolution of symptoms within 24 h of onset. In cases where onset time cannot be established, it will be considered to be the time when the patient was last known to be well.~3. Atrial Fibrillation (AF, paroxysmal or persistent). AF must be confirmed with ECG/Holter monitor, or by history All patients prescribed dabigatran according to the Canadian product label by the treating physician following their stroke/TIA. The decision to treat with dabigatran and the timing of the first dose will be determined by the attending physician, independent of the registry. All patients will have a CT scan or MRI, with findings consistent with an ischemic etiology of symptoms.~4. Ability to obtain informed consent obtained from patient or legally authorized representative.~Exclusion Criteria:~1. Acute or chronic renal failure, defined as eGFR \<30 ml/min (Cockcroft Gault formula).~2. Known hypersensitivity to dabigatran or any other contraindication to dabigatran therapy, as per Canadian label information.~3. Prior treatment with dabigatran or any other novel oral anticoagulant (including all Factor Xa antagonists). Treatment with warfarin prior to the stroke/TIA is acceptable, but enrolment cannot begin until the INR is ≤1.5.~4. Prior symptomatic ischemic stroke (TIA is not an exclusion criterion)~5. Any significant ongoing systemic bleeding risk, i.e. active GI/GU bleeding or recent major surgery.~6. Clinically significant recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of each Investigator.~7. Hereditary or acquired hemorrhagic diathesis.~8. Anticipated inability to comply with follow up.~9. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).